Rosiglitazone and pioglitazone aggravate doxorubicin-induced cardiomyopathy in Wistar rats

Biomedicine and Aging Pathology

Volumn 1, Issue 1, 2011, Pages 65-71

  Saraogi, Priyadarshan ^a   Pillai, Krishna Kolappa ^a   Singh, Bhulan Kumar ^a   Dubey, Kiran ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Cardiomyopathy; Rosiglitazone; Thiazolidinediones

Indexed keywords

CATALASE; DOXORUBICIN; GLUTATHIONE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LACTATE DEHYDROGENASE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; ROSIGLITAZONE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CARDIOMYOPATHY; CELL VACUOLE; CHROMATIN CONDENSATION; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFECT; HEART MUSCLE; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MUSCLE FIBRIL; NONHUMAN; RAT; REVIEW; TISSUE HOMOGENATE; TISSUE INJURY; TRANSMISSION ELECTRON MICROSCOPY; WISTAR RAT;

EID: 79960451280     PISSN: 22105220     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomag.2010.12.001     Document Type: Review

References (36)

1. Gorgino F, Laviola L, Leonandini A. A pathophysiology of type 2 diabetes: rationale for different oral antidiabetic treatment strategies. Diabetes Res Clin Practice 2005;68:S22-9. (Pubitemid 40805488)
2. Elte JW, Blickle JF. Thiazolidinediones for the treatment of type 2 diabetes. Eur J Int Med 2007;18(1):18-25. (Pubitemid 46072729)
3. Nissen SE, Wolsky K. Effect of rosiglitazone on the risk of myocardial infraction and deaths from cardiovascular causes. New Eng J Med 2007;356(24):2457-70.
4. News. Weighing up the evidence. Nature 2007;447:512-3.
5. El-Hage. Peroxisome proliferators activated receptor (PPAR) agonist: clinical and cardiac safety considerations 2007. [Accessed: www.fda.oc/cder/ present/dia2006/El-Hage-cardiac safety.ppt].
6. Coudray C, Hida H, Boucher F, et al. Modulation by selenium supplementation of lipid peroxidation induced by chronic administration in rats. Nutrition 1995;11:512-6. (Pubitemid 26006214)
7. Singal PK, Iliskovik N. Doxorubicin-induced cardiomyopathy. N Eng J Med 1998;339:900-5. (Pubitemid 28446849)
8. Sorenson K, Lewitt G, Bull C, et al. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival and late cardiotoxicity. J Clin Oncol 1997;15:61-8. (Pubitemid 27020558)
9. Doroshow JH. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 1983;43:460-72. (Pubitemid 13193830)
10. Singal PK, Iliskovik N, Li T, et al. Adriamycin cardiomyopathy: pathophysiology and prevention. Fed Am Soc Exp Biol 1997;11:931-6. (Pubitemid 27425894)
11. Myers CE, McGuire WP, Liss RH, et al. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977;19:165-7. (Pubitemid 8140036)
12. Singal PK, Deally CM, Weinberg LE. Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol 1987;19:817-28. (Pubitemid 17144746)
13. Singh BK, Pathan RA, Pillai KK, et al. Diclofenac sodium. A nonselective nonsteroidal anti-Inflammatory drug, aggravates doxorubicin induced cardiomyopathy in rats. J Cardiovascular Pharmacol 2010;55(2):139-44.
14. Lum G, Gambino SR. A comparision of serum versus heparinized plasma for routine chemistry test. American J Clinical Pathol 1974;62:108.
15. Friedwald WT, Levy RI, Fredrickson DS. Estimation of concentration of LDL cholesterol in plasma without use of preparative ultracentrifuge. Clinical Chem 1972;18:499.
16. Lowary OH, Rosebrough NJ, Farr AL, et al. Protein measuremet with the folin phenol measurement. J Biol Chem 1951;193:265-75.
17. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reactions. Anal Biochem 1979;95:359-64.
18. Sedlak J, Lindsay RH. Estimation of total, protein bound and nonprotein sulfhydryl group in tissue with Ellman's reagent. Anal biochem 1968;25:192-205.
19. Marklund S, Marklund G. Involvement of the superoxide anion radical in the autoxidation by pyrogallol and convenient assay for superoxide dismutase. Eur J Biochem 1974;47:469-74.
20. Clairborne A. Assay of catalase. In: Greenwald RA, editor. Handbook of Methods of Oxygen Free Radicals Research. Boca Raton, FL:CRC Press; 1985. p. 283-284.
21. David GFX, Herbert J, Wright CDS. The ultrastructre of pineal ganglion in the ferret. J Anat 1973;115:79.
22. Gosalvez M, Van Rossuns GD, Blanco MF. Inhibition of sodium potassium activated adenosine 5' triphosphate and ion transport by adriamycin. Cancer Res 1979;39:257-61. (Pubitemid 9090441)
23. Bertani T, Pozzoni R, Delaini F, et al. Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events. Lab Inves 1982;46(1):16-23. (Pubitemid 12167012)
24. Bizzi A, Ceriani L, Gerundino M, et al. Adriamycin causes hyperlipidemia as a consequence of nephrotoxicity. Toxicol Lett 1983;18(3):291-300. (Pubitemid 13018026)
25. Kashyap ML, DeMendoza SG, Campbell M, et al. Lipoprotein lipase activator deficiency in very low density lipoproteins in rat nephritic syndrome. Experientia 1978;34(8):1044-5. (Pubitemid 8390303)
26. Sevanian A, Hochstein P. Mechanisms and consequences of lipid peroxidation in biological systems. Ann Rev Nutr 1985;5:365-90.
27. Hickey EJ, Raje RR, Reid VE, et al. Diclofenac induced in vivo nephrotoxicity may involve oxidative stress-mediated massive genomic DNA fragmentation and apoptotic cell death. Free Radic Biol Med 2001;31:139-52. (Pubitemid 32607581)
28. Ito H, Nakano I, Kinoshita M, et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model. Lab Inves 2003;83:1715-21. (Pubitemid 38018534)
29. Goldbourt U, Yaari S, Medalie JH. Isolated Low HDL Cholesterol as a risk factor for coronary heart disease mortality: a 21-year follow-up of 8000 man. Arterioscl Thromb Vasc Biol 1997;17:107-13. (Pubitemid 27057331)
30. Timao L, Singal PK. Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol. Circulation 2000;102:2105-10.
31. Bassenge E, Sommer O, Schwenmmer M, et al. Antioxidant pyruvate inhibits cardiac formation of reactive oxygen species through changes in redox state. Am J Physiol Heart Circ Physiol 2000;279:H2431-8.
32. Yki-Jarvinen H, Thiazolidinedione. New Eng J Med 2004;351:1106-8.
33. Singh S, Loke YK. Thiazolidinediones and heart failure: a teleo analysis. Diabetes Care 2007;30:2148-53. (Pubitemid 47219440)
34. Home PD. Rosiglitazone evaluated for cardiovascular outcomes - An interim analysis. New Eng J Med 2007;367:28-38. (Pubitemid 47026732)
35. Gerstein HC, Yusuf S, Holman RR, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance on impaired fasting glucose: A randomized controlled trial (DREAM). Lancet 2006;6737(66):69420-8.
36. Kahn S, Haffiner S, Heise M, et al. Glycemic durability of rosiglitazone metformin or glyburide monotherapy. New Eng J Med 2006;355(23):2427-43. (Pubitemid 44903747)